0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
7
Media Outlet Article / Coverage
IASLC Lung Cancer Considered ASCO 2024 Highlights Part 1 - Plenary
IASLC Lung Cancer News ADRIATIC Demonstrates Meaningful Improvements in OS,
PFS in Patients with Limited-stage SCLC
Korea Biomedical Review [ASCO2024] Durvalumab Shines as Consolidation Therapy
for Limited-Stage SCLC
MedCity News At ASCO, AstraZeneca Adds Data Supporting Expanded
Use of Its Drugs in Lung Cancer
MedPage Today Limited-Stage SCLC Gets a New Standard of Care With
Consolidation Durvalumab
MedPage Today No Survival Advantage With Sacituzumab Over Chemo in
Previously Treated NSCLC
MedPage Today 'Practice Changing' Trial for Inoperable Locally Advanced
NSCLC
MedPage Today Unprecedented PFS Results in ALK-Positive Lung Cancer
Trial
Medscape 'Impressive' 5-Year Progression-Free Survival With Lorlatinib
in ALK+ NSCLC
Medscape 'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
OncLive Consolidation Durvalumab to Become New SOC for LS-
SCLC After Chemoradiation
OncLive Dr Spigel on the Efficacy of Durvalumab Consolidation
Therapy in LS-SCLC
Onco Info TV ADRIATIC Trial: A New Beginning for The Treatment of LS-SCLC
Oncology Learning Network Lorlatinib Provides Longest Progression Free Survival Ever
Seen for Patients With Advanced ALK-Positive Non-Small
Cell Lung Cancer
Oncology News Central "Groundbreaking" Data Upend Practice in Lung Cancer:
Consolidation Durvalumab Extends Survival in LS-SCLC
Oncology Nursing News Osimertinib May Change Standard of Care for Stage III
EGFR+ NSCLC After Definitive Chemoradiation
David Spigel, MD
SCRI
Continued ➔
